EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
EGFR-TKIs are the standard first-line treatment option for EGFR-mutant NSCLC. After a
randomized phase II trial, JO25567 was presented at 2014 ASCO, the synergistic effect of
progression-free survival(PFS) could be expected when EGFR TKI, Gefitinib is combined with
Antiangiogenesis agent thalidomide, Therefore Chinese data of treating EGFR mutation positive
NSCLC patients with Gefitinib and thalidomide is significantly necessary for developing new
standard treatment in first-line therapy in Chinese EGFR mutant NSCLC patients.
In this study, The investigators will investigate the efficacy and safety of Gefitinib and
thalidomide combination compare to Gefitinib alone in Chinese EGFR-mutant NSCLC patients.